Estrella Immunopharma, Inc. (ESLA)
ESLANASDAQ-CMBiotechnology: Biological Products (No Diagnostic Substances)
$0.7801
+0.0191 (+2.51%) today
Closed, Nov 11, 4:00 PM ET
- Market cap
- $34.53m
- P/E
- –
- EPS, last 4 quarters
- $-0.2400
- Dividend yield
- –
- Day range
- –
- 52-week range
- $0.2400 to $2.71
- Average volume
- –
- Previous close
- $0.7610
Earnings
next estimate $-0.0800Next report
Sep 2025
–
Dec 2025
–
Mar 2026
–
Jun 2026
+44.4%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$4.80m | -$613.0k | -$2.29m | -$1.98m |
| Net income | -$4.80m | -$613.0k | -$2.29m | -$2.31m |
News
5 latest- Estrella Immunopharma, Inc. Appoints Cynthia Pussinen as CEO on October 25, 2026Fintel · Nov 2, 2026
- Estrella Immunopharma Names Cynthia Pussinen CEO, Succeeding Cheng Liu RTTNews · Oct 26, 2026
- Estrella Adds Cleveland Site To STARLIGHT-1 Trial For B-cell Lymphoma; Stock Up RTTNews · Aug 12, 2026
- D. Boral Capital Maintains Estrella Immunopharma (ESLA) Buy RecommendationFintel · Nov 3, 2025
- D. Boral Capital Initiates Coverage of Estrella Immunopharma (ESLA) with Buy RecommendationFintel · Feb 18, 2025
The company
Estrella is a clinical-stage biopharmaceutical company developing CD19- and CD22-targeted ARTEMIS T-cell therapies to treat cancers and autoimmune diseases. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and other diseases. To accomplish this mission, Estrella's lead product candidate, EB103, utilizes Eureka's ARTEMIS technology to target CD19, a protein expressed on the surface of almost all B-cell leukemias and lymphomas. Estrella is also developing EB104, which utilizes Eureka's ARTEMIS technology to target not only CD19, but also CD22, another protein expressed on the surface of most B-cell malignancies.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- estrellabio.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.